Profile data is unavailable for this security.
About the company
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
- Revenue in USD (TTM)14.61m
- Net income in USD-133.03m
- Incorporated2015
- Employees231.00
- LocationGritstone bio Inc5959 HORTON STREET, SUITE 300EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 871-6100
- Fax+1 (510) 597-1488
- Websitehttps://gritstonebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maia Biotechnology Inc | 0.00 | -28.08m | 69.09m | 13.00 | -- | 21.70 | -- | -- | -1.62 | -1.62 | 0.00 | 0.1332 | 0.00 | -- | -- | 0.00 | -251.96 | -- | -362.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
| Precision BioSciences Inc | 87.64m | 15.79m | 69.52m | 110.00 | -- | 0.9162 | 3.32 | 0.7932 | -0.1363 | 0.202 | 17.59 | 10.49 | 0.5044 | -- | 79.03 | 804,036.70 | 9.09 | -35.35 | 12.24 | -44.22 | -- | -- | 18.02 | -147.50 | -- | -- | 0.2314 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| OS Therapies Inc | 0.00 | -6.55m | 69.77m | 4.00 | -- | -- | -- | -- | -0.3011 | -0.3011 | 0.00 | -1.32 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.9763 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Spero Therapeutics Inc | 118.46m | 17.46m | 71.89m | 46.00 | 4.20 | 0.8923 | 4.08 | 0.6068 | 0.3169 | 0.3169 | 2.21 | 1.49 | 0.9524 | -- | 4.11 | 2,575,196.00 | 14.03 | -35.52 | 18.79 | -41.75 | -- | -- | 14.74 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| MDxHealth SA | 80.74m | -40.80m | 72.04m | 300.00 | -- | -- | -- | 0.8922 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Gritstone bio Inc | 14.61m | -133.03m | 74.14m | 231.00 | -- | 3.33 | -- | 5.07 | -1.35 | -1.35 | 0.1391 | 0.1884 | 0.08 | -- | 49.20 | 63,251.08 | -72.86 | -48.08 | -83.37 | -55.18 | -- | -- | -910.50 | -573.71 | -- | -97.11 | 0.6461 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| IO Biotech Inc | 0.00 | -88.00m | 74.45m | 68.00 | -- | 0.7733 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Omega Therapeutics Inc | 6.31m | -78.90m | 75.56m | 93.00 | -- | 2.88 | -- | 11.97 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Genelux Corp | 8.00k | -26.54m | 76.67m | 23.00 | -- | 2.01 | -- | 9,583.59 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Renovaro Inc | 0.00 | -88.12m | 76.70m | 11.00 | -- | 0.4549 | -- | -- | -1.08 | -1.08 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -60.56 | -27.81 | -68.21 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -48.88m | 77.28m | 63.00 | -- | 0.3606 | -- | -- | -0.9662 | -0.9662 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -20.38 | -21.16 | -21.39 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -34.44m | 77.84m | 16.00 | -- | 23.99 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | 57.92m | 78.50m | 17.00 | 1.22 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
| Cidara Therapeutics Inc | 31.58m | -116.17m | 79.32m | 69.00 | -- | 0.3933 | -- | 2.51 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
Data as of Sep 20 2024. Currency figures normalised to Gritstone bio Inc's reporting currency: US Dollar USD
24.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 30 Jun 2024 | 5.11m | 4.33% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.61m | 3.91% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 4.44m | 3.76% |
| Alyeska Investment Group LPas of 30 Jun 2024 | 3.46m | 2.93% |
| DWS Investments (UK) Ltd.as of 30 Jun 2024 | 3.23m | 2.73% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 3.03m | 2.57% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 1.61m | 1.36% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 1.14m | 0.96% |
| Millennium Management LLCas of 30 Jun 2024 | 1.11m | 0.94% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.05m | 0.89% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
